← Back to headlines
AbbVie Lowers Q1 and FY 2026 Earnings Outlook After R&D Charge
AbbVie has revised down its earnings outlook for the first quarter and full fiscal year 2026, following a significant $744 million research and development charge.
6 Apr, 11:18 — 6 Apr, 11:18
Sources
Showing 1 of 1 sources
Related Stories
Manila Water's Upper Wawa Dam Project Shortlisted for Global Water Award
just now
Philippine Senator Legarda Files Bayanihan 3 Act for Oil Crisis Relief
just now
DPWH Completes Phase 1 of Edsa Rehabilitation in Manila
just now
Philippine Lawmaker Calls for Penalties Against Spreaders of Fake 'Energy Lockdown' News
just now